Yes, Gilenya Treats Relapsing Forms of Multiple Sclerosis
Gilenya (fingolimod) is FDA-approved for adults and children aged 10 years and older with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[1] It reduces relapse frequency and delays disability progression by trapping immune cells in lymph nodes, limiting their attack on the central nervous system.
How Gilenya Fits into MS Treatment Options
Gilenya belongs to the sphingosine 1-phosphate receptor modulators class, distinct from injectables like interferons or monoclonal antibodies like Ocrevus. It's taken as a daily oral capsule, with first-dose monitoring required due to heart rate effects. Common alternatives include Tecfidera (dimethyl fumarate) for relapsing-remitting MS or Kesimpta (ofatumumab) for similar patients.[1][2]
What Happens During the First Dose?
Patients receive the initial dose in a medical setting for 6 hours to watch for bradycardia or atrioventricular block, which occur in about 1-5% of cases. Eye exams check for macular edema, a risk in 0.4% of users.[1]
Common Side Effects Patients Report
Headaches, back pain, elevated liver enzymes, and infections top the list. Serious risks include progressive multifocal leukoencephalopathy (rare, linked to prior treatments) and increased herpes infections. Long-term data show a slight rise in skin cancer risk.[1][3]
When Does Gilenya's Patent Expire?
The primary composition-of-matter patent for fingolimod expired in the U.S. in 2019, allowing generic entry. However, formulation and method-of-use patents extend protection; check DrugPatentWatch.com for the latest expiry dates, currently projected into 2027 for some claims amid ongoing litigation.4
Can It Be Used in Primary Progressive MS?
No, Gilenya lacks approval for primary progressive MS, unlike Ocrevus, which targets that form.[1]
[1]: FDA Label for Gilenya (Novartis), accessed via FDA.gov
[2]: National MS Society Treatment Guidelines
[3]: Post-Marketing Safety Data (PMC)